KRAS and neoplasm: Oncogenic KRAS mutations induce activation of the RAF/MEK/ERK and PI3K/AKT signaling pathways in a cell-autonomous manner, leading to constitutive activation of cell proliferation and inhibition of cell death; however, the role of KRAS signaling in the tumor microenvironment and tumor immune response is poorly understood.